TNGX: Three White Soldiers detected on 6 Mar 2026

Three white soldiers pattern forming with 47.63% one-week gain, posting an unusually strong +7.39% upside reaction to Q4 2025 earnings reported today. Structure score 15.0 is near-maximum, signaling tight consolidation with clean higher lows. Breakout score 10.4 and volume score 8.4 reflect moderate confirmation—current volume at 17.97M shares (5.07x 20-day average) provided meaningful drive, but volume expansion could strengthen the setup. Price at $16.83 sits just 0.14 points below resistance at $16.97. RSI at 75.68 signals overbought conditions, typical post-earnings spike. The pattern targets $17.80 (conservative measure move) with key support anchor at $10.80.

Collaboration revenue hit $62.4M in 2025 as Tango booked a $101.6M net loss but expects its $343.1M cash to fund trials and pivotal work into 2028. Today's +7.39% post-FY 2025 reaction represents an unusually strong upside response versus prior earnings patterns, breaking historical -4.82% average move on earnings. In January 2026, the company announced the retirement of its founding Chief Executive Officer, Dr. Barbara Weber. She was succeeded by Dr. Malte Peters, a distinguished leader with extensive clinical development and leadership experience who has served on the Tango Board of Directors since 2018. Vopimetostat pivotal 2L pancreatic study start expected in 2026; initial phase 1/2 combo data with RAS(ON) inhibitors expected in 2026. The biotech sector context is bearish (regime -0.24), pressuring valuations.

A successful breakout would clear the $16.97 resistance level and target $17.80 based on conservative measured move. Volume confirmation remains moderate at 5.07x average; breakout should sustain elevated volume (ideally >6x) to confirm conviction. Historical win_probability of 71.54% indicates two-thirds of similar setups reach the target. The pattern invalidates below $10.80 support—a breach would signal failed continuation and potential mean-reversion. Given the 66.96% three-month gain and 1,533.98% move off 52-week lows, price action is stretched but still held above all major moving averages.

Market reactions were mixed, including sharp downside after the Q3 2024 update and gains after Q1–Q2 2025, showing binary clinical data risk. Sector regime is bearish, limiting multiple expansion. RSI at 75.68 signals extreme overbought territory—reversion would be natural. Earnings releases have often seen negative or muted reactions despite generally constructive clinical and cash updates, meaning today's spike could reverse. Beta of 1.23 amplifies market downturns. Clinical execution risk remains—pivotal pancreatic study initiation in 2026 is critical; any delay or safety signals would crater the stock. Regulatory risk is present with early-stage Phase 1/2 data; no Phase 3 readouts expected until 2026-2027, leaving 18+ months of pipeline uncertainty.